Dynamics of three-dimensional telomere profiles of circulating tumor cells in patients with high-risk prostate cancer who are under going androgen deprivation and radiation therapies

作者：Wark Landon; Klonisch Thomas; Awe Julius; LeClerc Cecile; Dyck Brandon; Quon Harvey^*; Mai Sabine^*

来源：Urologic Oncology-Seminars and Original Investigations, 2017, 35(3): 112.e1-112.e11.

DOI：10.1016/j.urolonc.2016.10.018

• High-risk prostate cancer
• Telomeres
• Circulating tumor cells
• Biomarkers

Introduction:Accurate assessment and monitoring of the therapeutic efficacy of locally advanced prostate cancer remains a major clinical challenge. Contrary to prostate biopsies, circulating tumor cells (CTCs) are a cellular source repeatedly obtainable by blood sampling and could serve as a surrogate marker for treatment efficacy. In this study, we used size-based filtration to isolate and enumerate CTCs from the blood of 20 patients with high-risk (any one of cT3, Gleason 810, or prostate-specific antigen>20 ng/ml), nonmetastatic, and treatment-naive prostate cancer before and after androgen deprivation therapy (ADT) and radiation therapy (RT).
Materials and methods:We performed 3D telomere-specific quantitative fluorescence in situ hybridization on isolated CTCs to determine 3D telomere profiles for each patient before and throughout the course of both ADT and RT.
Results:Based on the distinct 3D telomere signatures of CTC before treatment, patients were divided into 3 groups. ADT and RT resulted in distinct changes in 3D telomere signatures of CTCs, which were unique for each of the 3 patient groups.
Conclusion:The ability of 3D telomere analysis of CTCs to identify disease heterogeneity among a clinically homogeneous group of patients, which reveals differences in therapeutic responses, provides a new opportunity for better treatment monitoring and management of patients with high-risk prostate cancer.

• 出版日期2017-3